|
1.
Share Success: Letters From Readers
Letter
I: From Julie S.
Received
at ShareSuccess @ ezorbonline.com 12/28/17 at 9:11 AM
(Unedited)
Hello,
Speaking of bone spurs it reminded me of my own bone spur on the top of my right hand. It is a bump that sits on the top of my right hand. Anytime I make a fist or start to write or hold the mouse, it looks too obvious and too big to be present on that part of my body.
It bothered me of course especially if I am with the company of other people. I would often keep my right hand on my lap to avoid any curious questions about it. I have just noticed now that the bone spur on top of my right hand totally disappeared. I have not even noticed it being gone until I read your recent ezorb news on bone spurs.
I have been taking ezorb calcium aspartate anhydrous for a good 5 years and I have always felt good through out my body and have been pretty agile in my walking and doing my daily chores.
My son oftentimes remarked how a 71 year old woman can be so mobile. I attribute all of this to my daily intake of this ezorb supplement. It has helped me to do my daily long walks, to shop and carry, to get up every morning without any pain from arthritis, and to feel good throughout the day doing my routine. If I miss a day taking it I really feel the difference.
I will never give up ezorb calcium aspartate anhydrous and will continue to recommend it to my friends. Thank you Ezorb for being available to help us feel good.
J.S.
Letter
II: From Ellen
Received
at Testimonial
Submit Form Wednesday, January 17, 2018 at 01:56:14
(Unedited)
Hi, my name is Ellen. 81 yr young female.
I have been taking Ezorb and Marvlix for about 6/8 months. When I started taking them, my blood pressure readings were 165 to 185 over 65 to 95. Since about 2 weeks after starting to take them all of my readings have been from 116 to 145 over 65 to 80. That sure helps the old "ticker."
Also the reason I tried them in the first place was to see if it would give me any help with my COPD. It has indeed. It is now much easier to breathe.
Also a week ago I had a Ultrasound Examination of the heart, including Color-depicted Blood flow rate, Direction and valve Function. Last test was done in 2014. Results this time said everything was the same as in 2014 except the Left Ventricle (which pumps oxygenated blood into the Aorta). That was slightly improved, which the nurse said was unusual. I credit that to the Marvlix.
I also have Osteoporosis. My Dr. prescribed a prescription. First 2 months seemed O.K. Third month had bad reactions and had to stop taking. So I started the Ezorb.
Short time later had a bone density test and the Dr. called me in to discuss how bad it was and prescribed Ibandronate sodium 150 mg tablets that you take once a month. Told him I was taking the Ezorb and wanted to get another bone density test in 3 months to see if there was any improvement with that first. He looked over the literature and said that the insurance companies only pay for the test every two years because it takes that long to see any improvement. So apparently any of the prescriptions take that long to show any improvement. Guess I'll call my insurance provider and if they won't pay, find out how much it costs to pay for the Bone Density Test.
So far, very happy with both products. Give them a try.
***************************************************
From
the Desk of EZorb Newsletter Editor:
This
newsletter is now read by over 95,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess @ ezorbonline.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public. If your testimonial is selected for publication, you will receive a gift to show
our appreciation of your effort.
2.
Research News: Aggressive Hypertension Treatment Doesn't Help Atrial Fibrillation
Reducing target blood pressure (BP) does not decrease the incidence of recurrent arrhythmia among patients undergoing catheter ablation for atrial fibrillation (AF), results of a randomized trial suggest.
In the SMAC-AF (Substrate Modification with Aggressive Blood Pressure Control) trial, patients with AF whose BP was greater than 130/80 mmHg at baseline were assigned to receive either aggressive (target BP lt 120/80 mmHg) or standard (target BP lt 140/90 mmHg) antihypertensive treatment prior to catheter ablation.
As reported in Circulation, mean BP was significantly lower after a median 3.5 months of aggressive treatment compared with 3.1 months of standard treatment, at 123.2/76.7 mmHg versus 135.4/80.8 mmHg. Baseline measurements were an average of 142.9/84.9 mmHg and 142.2/84.3 mmHg, respectively.
However, there was no significant difference in the rate of recurrent symptomatic AF, atrial tachycardia, or atrial flutter occurring more than 3 months post-ablation between the aggressive and standard treatment groups, with corresponding rates of 61.4% and 61.2%.
The team observed a higher incidence of hypotension requiring medication adjustment among patients receiving aggressive compared with standard BP therapy, at 26.1% versus 0%, and 2.2% of participants in the aggressive treatment group were hospitalized due to effects of the study treatment, compared with none in the standard treatment group.
In prespecified subgroup analyses, the researchers found that recurrent arrhythmia occurred significantly less frequently with aggressive compared with standard treatment among patients aged 61 years and older, but that this was not true among younger patients (55.6 vs 76.9% and 67.4 vs 47.8%, respectively).
"The significance of this finding is uncertain in the context of the globally neutral result," say Ratika Parkash (QEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada) and study co-authors. However, they note that there was a larger reduction in BP among patients in the older age group compared with younger participants, which "lends credence to this observation."
Additionally, there was a significant reduction in recurrent arrhythmia with aggressive versus standard treatment in the subgroup of patients with systolic blood pressure of less than 140 mmHg at baseline, but not in those with higher BP.
Therefore, "benefit from aggressive BP treatment may need to begin further upstream, before patients reach the threshold of a high AF symptom burden requiring catheter ablation," the authors suggest.
And the team concludes: "Determining at which point in the atrial substrate pathway where upstream therapy would [reduce] atrial arrhythmia could result in significant benefits to the increasing population of AF patients."
Original article appeared in 03-01-2017 | Arrhythmia | News | Article.
3.
Useful Links
Frequently
Asked Questions & Answers
EZorb
Clinical Studies
Marvlix
Benefits
Order
Now
4.
Calcium
Absorption Test
EZorb
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test @ elixirindustry.com
for a copy of the instructions.
5.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix. |
